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Summary 
Immune surveillance  against tumors usually depends  on T  cell recognition of tumor antigens 
presented by major histocompatibility complex (MHC)  molecules, whereas MHC  class I  tu- 
mors may be controlled by natural killer (NK) cells.  Perforin-dependent cytotoxicity is a major 
effector function ofCD8 + MHC  class I-restricted T  cells  and of NK cells.  Here, we used per- 
forin-deficient  C57BL/6  (PKO)  mice to study involvement of perforin and Fas ligand in tu- 
mor surveillance in vivo. 
We induced tumors in PKO and normal C57BL/6 mice by (a) injection of different synge- 
neic tumor cell lines of different tissue origin in naive and primed mice;  (b) administration  of 
the  chemical carcinogens methylcholanthrene  (MCA)  or 12-O-tetradecanoylphorbol-13-ace- 
tare  (TPA)  plus  7,12-dimethylbenzanthracene  (DMBA),  or (c)  by injection  of acutely onco- 
genic Moloney sarcoma virus. The first set of models analyzes the defense against a tumor load 
given at once, whereas the last two sets give information on immune defense against tumors at 
the very moment of their generation.  Most of the tumor cell lines tested were eliminated  10- 
100-fold better by C57BL/6 mice in an unprimed situation; after priming, the differences were 
more  pronounced.  Lymphoma  cells  transfected  with  Fas  were  controlled  10-fold better  by 
PKO and C57BL/6 mice when compared to untransfected control cells,  indicating some role 
for FasL in tumor control.  MCA-induced tumors arose more rapidly and with a higher inci- 
dence in PKO mice compared to C57BL/6  or CDS-deficient  mice.  DMBA+TPA-induced 
skin  papillomas  arose  with  similar  high  incidence  and  comparable  kinetics  in  both  mouse 
strains.  C57BL/6 and PKO mice have a similar incidence ofMoloney murine sarcoma and leu- 
kemia virus-induced sarcomas, but tumors are larger and regression is retarded in PKO mice. 
Thus, perform-dependent  cytotoxicity is not only a crucial mechanism of both cytotoxic 
T  lymphocyte- and  NK-dependent  resistance  to injected  tumor cell lines,  but  also  operates 
during  viral  and  chemical  carcinogenesis  in  vivo.  Experiments  addressing  the  role  of Fas- 
dependent  cytotoxlcity by studying resistance  to  tumor cell lines  that were stably transfected 
with Fas neither provided evidence for a major role of Fas nor excluded a minor contribution 
of Fas in tumor surveillance. 
T 
umor cells arise in individuals as a result of exposure to 
rnutagenic  chemicals,  radiation,  viruses,  or spontane- 
ous mutations  (1).  Whether or not an individual succumbs 
to the tumor depends  on the balance between  growth ki- 
netics and metastatic  capacity of the tumor versus the abil- 
ity of the host to control the tumor.  For this,  the host has 
two major mechanisms at its  disposal: innate  and acqmred 
immunity.  Innate immunity (e.g.,  NK cells)  is not antigen 
specific and is able to act quickly and without priming. Ac- 
quired  immunity  depends  on  primxng,  is  therefore  rela- 
tlvely slow but highly specific, and has a memory. A  tumor 
can prime  acquired immunity if it presents  tumor-specific 
antigens in the context of MHC class I or class II molecules 
to  CD8 +  or  CD4 +  T  cells,  respectively  (1-3).  Further- 
more, expression  of costimulatory molecules  (e.g., B7,  in- 
tracellular adhesion molecule-I, and LFA-3) has been shown 
to dramatically increase the efficiency of prinung in certain 
instances  (4-7).  Under selective pressure,  however,  tumor 
escape variants that lack MHC  class  I or II molecules,  co- 
stimulatory  molecules,  or  tumor-specific  antigens  (8-11) 
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expression are  efficiently controlled in vivo by  NK  cells 
(12, 13) in a strictly perforin-dependent way (13). 
Perforin-deficient (PKO) 1 mice have been generated on 
a  C57BL/6  genetic  background  (H-2  b)  by  homologous 
recombination and  are  healthy  under  specific  pathogen- 
free  conditions (14).  PKO  mice  completely lack perforin- 
dependent cytotoxicity, whereas  the  Fas  (CD95)/FasLigand 
(FasL)--dependent cytotoxic pathway is unimpaired (14-22). 
Therefore, PKO mice allow the assessment of the relative 
contribution of each of the two major cell-mediated cyto- 
toxic  pathways  to  a  variety of immune responses in vivo 
and in vitro  (14,  15,  17-22).  We  have  shown previously 
that  the  defense against infection with the  noncytopathic 
lymphocytic choriomeningitis virus (LCMV) or, to a lesser 
extent,  with  the  intracellular bacterium Listeria monocyto- 
genes depends on perforin-dependent cytotoxicity (14, 17, 23). 
Control of syngeneic MC57G fibrosarcoma cells was 10-fold 
better  in  C57BL/6  mice  compared  to  PKO  mice  (14). 
Also, the development ofinsuhn-dependent  diabetes melli- 
tus in a  transgenic model  (24)  is  perforln dependent.  On 
the  other  hand,  PKO  mice  were  normal with respect  to 
control of infection with cytopathic viruses like vaccinia vi- 
rus (VV) or Semliki forest virus (25). Finally, a role for per- 
forin-dependent cytotoxicity was demonstrated in rejection 
of MHC  class  1-disparate allografts such as heart  (26)  and 
allogeneic tumor cell lines (27),  as well as in mixed lym- 
phocyte reactions in vitro (14,  15), and in GVHD (28). 
Here, we  evaluate the role of perforin- and Fas-depen- 
dent cytotoxicity in the control of a variety of established, 
transplantable syngeneic MHC  class I + tumor cells in vivo 
and assess the susceptibility of PKO mice to primary indi- 
vidually arising tumors  induced by  chemical  carcinogens 
and by an oncogenlc virus. 
thracene-induced T lymphoma (American Type Culture Collec- 
tion [ATCC], Rockville, MD). B16 is a spontaneous melanoma, 
MC57G is a methylcholanthrene-induced  fibrosarcoma  (31), and 
MBL-2 is Moloney virus-reduced lymphoma. N1 are EL-4 cells 
stably transfected with the nucleoprotein (NP) of vesicular stoma- 
titis virus (VSV), and V1  is a mock-transfected control (N1  and 
V1  were  originally obtained  from  L.  Lefrancois,  Division of 
Rheumatology,  Connecticut Health  Center,  Farmington, CT; 
32).  SR23B  adenovirus type 5  early region I  (Ad5EI)  +  EJras 
transformed tumor cell line was generated from mouse embry- 
onic cells as described  previously (33) and contains an Ad5E1B- 
encoded CTL epltope.  All cell lines were of C57BL/6 origin and 
were maintained in IMDM supplemented with 5% FCS and anti- 
biotics. 
Monoclonal rat anti-mouse CD4 (YTS191.1)  and monoclonal 
rat  anti-mouse CD8  (YTS169.4)  were originally obtained from 
Dr. H. Waldmann (Dunn School of Pathology,  Oxford, UK; 34). 
Treatment involved injection of 2 mg l.p. of the appropriate  anti- 
body.  Efficiency  of depletion was  checked  by FACS  ® analysis 
(Becton Dickinson &  Co.).  Purified monoclonal hamster  anti- 
mouse  TNF-0~  TN3-19.12  has  been  described  (35) and  was 
kindly provided  by  Dr.  R.  Schrelber  (Washington School  of 
Medicine, St. Louis, MO); TN3-19.12 was used in vivo at 0.25 
mg/wk (two injections maximal) to neutralize TNF-ot. 
VSV Indiana (Mudd-Summer isolate) was originally obtained 
from Dr. D. Kolakofsky (University of Geneva, Geneva, Switzer- 
land) and were grown on BHK21  (baby hamster kidney, ATCC 
CRL 8544) cells infected with low multiplicity of infection (moi) 
and plaqued on Veto cells. VV expressing the NP of VSV (VV- 
VSV-NP) was kindly given by Dr. B. Moss (National Institutes of 
Health,  Bethesda,  MD;  36).  VV  expressing  FasL has  been de- 
scribed  (37). All VV stocks were made on BSC40 cells. LCMV, 
isolate WE (LCMV-WE), was initially obtained from Dr. F. Leh- 
mann-Grube (Heinnch-Pette Institfit fiir Experimental Virologie 
und Immunologle, Universlt~it Hamburg, Germany; 38) and was 
propagated  in L929 fibroblast cells. Moloney murlne sarcoma and 
leukemia virus  (MoMSV)  complex was  prepared  and tltered as 
described previously (39). 
Materials  and Methods 
Mice 
Inbred C57BL/6 mice were  obtained from the  Institute ffir 
Zuchthygiene (University of Zi.irich, Switzerland). PKO (14), CD8- 
deficient  mice  (CD8-/-;  29),  and  RAG-2-deficient  mice 
(1LAG2-/-; 30) have been described before and were bred under 
specific pathogen-free conditions in our own facilities. PKO mice 
had a C57BL/6 (H-2  b) background. Mice at least 7 wk old were 
used  in all experiments that were performed according to  can- 
tonal and federal laws on animal protection, which requires use of 
minimal numbers of experimental animals. 
Cell Lines, Antibodies,  attd  Viruses 
RMA is a mutagenized RBL-5 (Kauscher virus-reduced T lym- 
phoma  [12]) cell  line.  EL-4  is  a  9,10-dimethyl-l,2-benzan- 
IAbbrewatlons used in this paper: DMBA, 7,12-dimethylbenzanthracene; 
FasL, Fas hgand; LCMV, lymphocyUc chorlomeningitis  virus; LCMV- 
WE, LCMV isolate WE; MCA, methylcholanthrene;  moi, multlphclty  of 
infecuon; MoMSV, Moloney munne sarcoma virus, NP, nucleoprotem; 
PKO, perforin-deficlent  (mice); TPA, 12-O-tetradecanoylphorbol-13-ace- 
tare; VSV, vesicular  stomatms virus;  VV, vaccmta v~rus. 
Transfection of Cell Lines with Fas 
MBL-2 cells were stably transfected with a construct carrying 
the  mouse  Fas  gene and the  neomycin resistance  gene  (kindly 
provided by Dr. P.  Golstein, Centre d'Immunologle INSERM- 
CNRS, Marseille, France; 22) by electroporation and were subse- 
quently selected with 0.9  mg/ml geneticm (G418;  Glbco BRL, 
Basel, Switzerland). G418-resistant  cells were checked for Fas ex- 
pression by FACS  ® analysis: 1 million cells were incubated with 
10% normal hamster serum (15 rain at 4°C) followed by biotin- 
labeled  hamster  anti-mouse Fas (Jo-2:  PharMlngen, San Diego, 
CA) mAb. Cells were stained with streptavldin-FITC or strepta- 
vldin-PE. Fas  +  cell  lines were  subcloned by limiting diluuon. 
MBL-2 and MBL-2.Fas  cells were insensitive to TNF-mediated 
cytotoxiclty in vitro (data not shown). 
Fas-dependent Cytotoxicity Assay 
To test whether the transfected  Fas was funcuonal, Fas-trans- 
fected  (Fas  ÷)  and  control  (Fas)  cell  lines  were  labeled  with 
Na51CrO4 and were used as targets for FasL  + effectors. FasL  + ef- 
fectors were generated by infecting MC57G fibroblasts with VV- 
FasL (37) for 2 h with a multiplicity ofinfectin (moi) of 2. Effec- 
tors and targets (104 per well) were incubated for 5 h at 37°C in 
a  standard  51Cr release  assay. In  addition,  PKO  and  control 
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Tumor  Class I*  Class II*  Fas*  Fas-mediated lysis* 
MC57G  MCA fibrosarcoma  330  3  8  0 
MBL-2  Moloney B  lymphoma  1,100  3  21)  0 
MBL-ZFas  Moloney B lymphoma,  1,200  3  250  54 
Fas transfected 
EL-4  DMBA T  lymphoma  1,500  3  28  4 
1KMA  Rauscher T  lymphoma  1,300  3  33  6 
B 16  Melanoma  40  3  10  0 
S1K23B  Adeno-transfected  75  3  10  0 
embryonic cells 
*Cells were stained with biotin-labeled anti-MHC class I, anti-class II or ann-Fas mAb, followed by streptavidm-PE. Surface  expression of all cell 
lines was measured by FACS ® (CellQuest software)  xn one expenment and given m arbitrary umts with the fluroescence of second stage antibody 
alone set at 3. 
:~Percentage specific killing by VVFasL-infected MC57G effector cells at an E/T ratio of 10 m a 5-tl S~Cr release assay. 
C57BL/6  mice  were  infected  intravenously  with  200  PFU 
LCMV-WE.  8  d  later,  their spleens were tested in a  CTL  assay 
for LCMV-specific cytotoxicity on SlCr-labeled, LCMV peptide 
(GP33,  lmmunodomlnant  CTL  epitope  in  H-26  mlce)-loaded 
targets  (40).  Percentage of specific SlCr release  =  [(experimental 
release  -  spontaneous  release)/(maxlmal release  -  spontaneous 
release)]  ×  100%. 
Tumor Induction In  Vivo by Injection  of Tumor Cell Lines 
Normal Untreated Mice.  PKO  and  C57BL/6  mice  were  in- 
jected intraperitoneally with different amounts of viable tumor cells 
(Table  1).  Mice were monitored daily for tumor growth by de- 
termining their weight; they were killed if the weight increased 
to more than 15% compared to  noninjected controls.  In case of 
S1K23B  cells, subcutaneous tumor volume was deterrmned with a 
caliper measuring two perpendicular diameters. 
Effect of Priming with Viral  Antigens.  PKO  and  C57BL/6  mice 
were  primed  intravenously with 2  ×  10  ~' PFU  VSV,  with 2  X 
106 PFU VV-VSV-NP, or were left unprimed.  After 14 d,  mice 
were  rejected  lntraperitoneally  with  different  numbers  of N1 
(EL-4 thymoma expressing VSV-NP)  or V1  (control EL-4),  and 
tumor growth was momtored. 
Effect of Priming with Tumor  Antigens.  PKO  and C57BL/6 mice 
were primed intrapentoneally with 5  X  10  ~ irra&ated  (100  Gy) 
MBL-2  cells in 0.2  nil PBS  on days 0  and 7.  On day  14,  mice 
were  rejected intraperitoneally with different numbers  of viable 
MBL-2  or  MBL-2.Fas  cells  and  were  monitored  tbr  tumor 
growth.  Alternatively,  mice  were  primed  subcutaneously  with 
107 irradiated (25 Gy) SR23B  cells m  0.1  ml PBS on days 0  and 
14 and challenged subcutaneously on day 28 with the same num- 
ber of SR23B cells. 
Male mice were used for all experiments to avoid possible tu- 
mor rejection caused by T  cells recognizing the male antigen H-Y. 
Tumor Induction by Tumorigenic Agents 
Carcinogenic Chemicals.  Groups  of  10  C57BL/6,  PKO,  and 
CD8 -/  mice were  rejected subcutaneously in the left hind leg 
with  0.1  ml  corn  oil  containing  25,  100,  or  400  btg  methyl- 
cholanthrene  (MCA),  and mice were  monitored weekly  for  fi- 
brosarcoma development. 
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Alternatively,  100  ~1 acetone  containing  10  nmol  12-O-tet- 
radecanoyl-phorbol-13-acetate  (TPA)  and 3  nmol 7,12-dlmeth- 
ylbenzanthracene  (DMBA)  was  applied  twice  weekly  on  the 
shaved skin  of the back to  groups  of eight C57BL/6  and PKO 
mice.  Skin  application was  continued during the  course  of the 
experiment, and mice were observed twice per week for the de- 
velopment of papillomas (41). 
MoMSV.  Groups  of 5-10  C57BL/6  and  PKO  (untreated, 
anti-TNF-treated,  CD4-  or  CD8-depleted)  or  CD8  /-  mace 
were injected m  the left thigh with  100 ILl PBS i.m.  containing 
103  focus  forming  units  of MoMSV  complex,  as  has been  de- 
scribed (39). Mice were monitored for tumor growth, and tumor 
size was determined using a caliper measuring two perpendicular 
diameters. 
Isolation  and Culture of MCA-induced  Sarcomas 
When MCA-mduced sarcomas had reached a volume of ~0.5 
cm  3, mice were killed and tumors were removed asepucally. Tu- 
mors were  cut into small pieces  and were  trypsmlzed for 5  h  at 
room temperature,  clumps were  removed,  and single cells were 
cultured in IMDM supplemented with  10% FCS, glutamme, and 
antibiotics.  Cells  were  split when  they  reached  confluency.  All 
sarcomas could be kept in culture for at least 3  too.  The expres- 
sion of MHC  class  I, class  II, and Fas was determined by FACS  ® 
analysis. 
Statistical  Analysis 
Results were compared statistically using the unpaired Mann- 
Whitney U test. 
Results 
Petforin  Plays a Role in Surveillance  against Most 
Established  Tumor Cell Lines 
PKO  mice  and C57BL/6  mice were  rejected with syn- 
geneic tumor cell lines of different tissue origins, and tumor 
growth was monitored. 
Tumors of Nonlymphoid Origin.  B16  melanoma  cells  grew 
unrestricted in both C57BL/6  and PKO  mice,  even when Table 2.  Control  of Syngeneic Tumor Cell Lines by C57BL/6 
and PKO Mice 
C57BL/6  PKO 
Tumor  Primed*  Unprimed  Primed  Unprimed 
MC57G  ND  106 (4/4)  ND  105 (4/4) 
MBL-2  >106 (6/6)  104 (6/6)  105 (6/6)  <102 (6/6) 
MBL-2.Fas  >106 (4/4)  105 (6/6)  106 (2/4)  103 (6/6) 
R.MA  >106 (414)  104 (7•7)  >106 (4•4)  104 (6•6) 
RdViA-S  ND  104 (8/8)  ND  102 (8/8) 
EL-4  >106 (6/6)  104 (6/6)  <102 (6/6)  <102 (6/6) 
B  16  ND  102 (3/3)  ND  102 (3/3) 
The cell numbers in the table  represent the lowest number of tumor 
cells that  could not be controlled in vlvo. The numbers in brackets  are 
the number of mice with tumors out of the total number tested which 
were obtained In two to three independent experiments with groups of 
two to three rmce. 
*Mice were primed with tumor cells (MBL-2, P,  MA) by injection of 
5 X 106 irradiated  tumor cells (MBL-2,  MBL-2 Fas, P,  MA) at days -14 
and  -7  before tumor challenge  at day 0 or with viral anugens  (VSV, 
VV-VSV-NP) by ln  lecnon of 2  ×  106 PFU at day  -14 betbre tumor 
(VSV-NP-transfected or mock-transfected EL-4)  challenge  at day 0. 
as  little  as  100  cells  were  injected.  MC57G  fibrosarcoma 
cells were controlled 10-fold better by C57BL/6  mice than 
by PKO  mice (Table 2)  (14).  In contrast,  107  adenovirus  + 
ras-tranformed  mouse  embryonic  cells  (SR23B)  were  re- 
jected by both  unprimed  mouse  strains  (Fig.  1).  The  tumors 
were smaller in PKO  mice, suggesting even a better control 
by these  mice.  After priming  with  irradiated  SR23B  cells, 
both  mouse  strains  were  equally  protected  against  tumor 
growth  (data not shown). 
Tumors of Lymphoid Origin.  EL-4  and MBL-2  cells were 
controlled  100-1,000-fold  better  by  naive  C57BL/6  mice 
when  compared  to  naive PKO  mice  (Table  2  and  Fig.  4). 
Priming with  tumor  cells  (MBL-2)  even increased  the  re- 
sistance  against subsequent  challenge  100-fold in C57BL/6 
and PKO  mice  (Table  2).  As previously shown  (42),  EL-4 
tumor  cells  expressing  a  wral  antigen  derived  from  VSV 
(N1),  but  not  their  mock-transfected  counterparts  (V1) 
were  readily  controlled  by  mice  that  had  been  previously 
primed  with  the  virus  (Fig.  2).  In  PKO  mice,  however, 
both  N1  and  V1  showed  uncontrolled  growth,  indicating 
that  this  form  of antitumor  immunity  ~s  essentially  medi- 
ated by perforin.  P,  MA  cells, which  are related  to  MBL-2 
cells, however,  were controlled to  a  similar extent  in both 
naive  and  primed  C57BL/6  and  PKO  mice.  The  MHC 
class  I-  derivative  of RMA  cells,  P,.MA-S  (12),  was  con- 
trolled considerably better by C57BL/6  mice (13). 
The  data  shown in  Table 2  were  obtained  using two  to 
three  mice per group  in two to  three  independent  experi- 
ments in which established  tumor cell lines were  "titrated" 
into mice with  10-fold differences in cell number injected. 
If a  certain  tumor  dose  could  not  be  controlled,  then  this 
5 x 105 SR23B  s.c.  80 
70  --0-- B6 
60 ~KO 
O 
N  40 
so 
~  2o 
lO 
o 
5  10  15  20  25  d 
Figure  1.  Adenovlms  +  ras transformed  mouse  embryonic  cells are 
controlled  by perform-deficient  mice. C57BL/6 (0) and PKO (©) mice 
were gaven 5 ×  105 S1L23B cells (expressing AdSE1 and EJras) subcutane- 
ously on day 0, and tumor development was monitored  Each line repre- 
sents an Individual mouse. 
was the case in  100% of the mice tested and,  in addition,  a 
10-fold lower load of the  same  tumor  cell line was  always 
controlled. An exception to this was formed by MBL-2.Fas 
cells in primed PKO  mice: in both experiments, one out of 
two  mice  controlled  10  °  cells,  and  one  out  of two  con- 
trolled  10 s cells, but died after  106  cells, albeit with a  delay 
of 2  wk  compared  to  the  time  mice  usually  died  in  these 
experiments  (Fig. 4). 
Stable  Transfection of MBL-2 Lymphoma  Cells with 
Functional Fas 
MBL-2  cells were  transfected  with  an expression vector 
encoding  mouse  Fas  and  G418  resistance  by  electropora- 
tion,  and  G418-resistant  MBL-2  cells  were  subcloned 
twice.  One  of the  selected  subclones  (MBL-2.Fas9)  dis- 
played a homogeneous  expression pattern  of Fas  (Fig. 3  A) 
and was  killed by  FasL +  MC57G  cells  (Fig.  3  B).  Spleno- 
>60 
50 
=  40 
Me- 
"~--  20 
10 
•  B6  ]~ 
o  ,Ko  I  I 
eeomoe 
z 
EL4  transfectant  ~  "~  z  ~  . 
injected  >~  =o  .~  o  E 
priming  none  VSV  VV-VSVnp 
Figure  2.  Growth  of syngenelc  EL-4  thymoma  cells in primed and 
unprlmed C57BL/6 and perform-deficient  mice.  Mice were primed at 
day 0 with 2 ×  106 PFU live VSV, 2 ×  10" PFU hve recombinant VV- 
expressing VSV-NP, or were left unpnmed.  At day 14, mice were chal- 
lenged  lntrapentoneally  with  106  live VSV-NP-transfected  or  mock- 
transfected  EL-4 cells Mice were observed  dally for tumor growth by 
monitonng the weight of the mice. Mice were killed if the weight m- 
creased >15% compared  to unlnjected mice. Each point represents one 
mouse. 
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Figure 3.  Lysls  of Fas-transfected MBL-2 lymphoma cells by perform- 
deficient  effectors.  (A)  Fas-expresslon  of  Fas-  and  mock-transfected 
MBL-2 cells. 106 cells were stained with a blotmylated  monoclonal ham- 
ster  anti-mouse  Fas  antibody  0o-1)  followed by  streptavidln-FITC. 
Viable cells were gated by a combination of forward  and  90  ° side light 
scatter, and were analyzed with a FACScan ® cytofluorometer using loga- 
nthmic scales. Filled curve, MBL-2 cells; open curve, MBL-2 Fas cells. (B) 
Enhanced  lysls of Fas  + MBL-2 cells compared to Fas-  MBL-2 cells by 
FasL-expressing effectors m vitro. MC57G cells were infected wxth VV- 
FasL (moi =  2) for 3 h  and  were used as effectors to kill SlCr-labeled 
MBL-2 and MBL-2.Fas  target cells In a standard  5 h 51Cr release assay. 
The spontaneous  release of MBL-2 and  MBL-2.Fas  target  cells was  17 
and  14%, respectively.  (C) Fas + MBL-2 cells are lysed by perforin-defi- 
cient  effectors in vitro. PKO and control C57BL/6 mice were infected 
intravenously  wath 200' PFU LCMV-WE. After 8 d, splenocytes (effec- 
tors) were analyzed for ex vivo cytotoxlc acUwty using LCMV-specxfic 
peptlde  (GP33)-loaded  MBL-2 or MBL-2.Fas  target  cells in a standard 
51Cr release assay. Lysls of MBL-2 and MBL-2.Fas  without peptlde  was 
<5%  at  the  highest  E/T ratio,  and  spontaneous  release of targets  was 
<18% 
cytes  of PKO  and  C57BL/6  mice  that  had  been  infected 
with  LCMV  8  d  previously  killed  LCMV  glycoprotein 
(GP)33-1oaded MBL-2.Fas cells to a similar extent (Fig. 3  C). 
As  expected,  untransfected  MBL-2  cells  (virtually  Fas-, 
Fig.  3  A)  were killed by  C57BL/6  effectors, but  only to  a 
low  extent  b~¢  perforin-deficient  effectors  (14);  this  sug- 
gested  a  major  role  for  the  perforin-dependent  cytolytic 
pathway against Fas- or Fas  l°w targets.  Thus,  transfection of 
MBL-2  cells with Fas generated a cell line with a high, sta- 
ble, and functional expression of Fas. 
We  also transfected MC57G  and B16  cells with Fas and 
obtained  clones  with  high  expression.  In  vitro,  however, 
these cells remained insensitive to Fas/FasL-mediated  apop- 
tosis  (data not shown), probably because of a lack of crucial 
intracellular  signalling  molecules  downstream  of Fas  (43). 
Therefore,  no  in  vivo  experiments  were  performed  with 
MC57G.Fas  and B16.Fas cells. 
Resistance against Fas-transfected MBL-2  Cells 
To  evaluate  whether  growth  characteristics  of MBL-2 
cells were  influenced by  Fas,  MBL-2  and  MBL-2.Fas  cells 
were titrated  intraperitoneally  in RAG2 -/-  mice.  In addi- 
tion,  growth kinetics in vitro were compared.  We  did not 
observe  differences  in  tumor  take  or  tumor  growth  be- 
tween  MBL-2  and  MBL-2.Fas  cells  at  the  doses  tested 
(102-104-106,  RAG2  /-  mice  could  not  control  the  tu- 
mor)  in  RAG2 -/  mice  or  of proliferation  in  vitro  (data 
not shown).  The potency of Fas/FasL interactions in tumor 
surveillance  in  vivo  was  investigated  in  naive  or  primed 
mice.  Naive  C57BL/6  mice  controlled  103  MBL-2  cells 
and  104 MBL-2.Fas cells, but could not control an inoculum 
of 104  MBL-2  or  105  MBL-2.Fas.  As little as  102  MBL-2 
cells grew in an uncontrolled fashion in PKO  mice, whereas 
102  MBL-2.Fas  cells  were  rejected  (Fig.  4).  This  suggests 
that  in  an  unprimed  situation,  Fas/FasL  interactions  may 
contribute to tumor control. 
In  a  subsequent  experiment,  mice  were  primed  intra- 
peritoneally  with  4  million  irradiated  MBL-2  cells.  Mice 
were subsequently challenged with different numbers  of vi- 
able MBL-2  or MBL-2.Fas tumor  cells, and tumor growth 
was  monitored.  Primed  C57BL/6  mice  controlled  the 
growth  of >106  MBL-2  or MBL-2.Fas  cells; on the  other 
hand,  primed PKO  mice exhibited tumor growth after in- 
jection  of 105  MBL-2  cells.  Two  out  of four  PKO  mice 
could  eliminate  105  MBL-2.Fas  cells,  whereas  the  other 
one  displayed  delayed  tumor  growth  (Table  2).  Thus, 
priming  with  irradiated  MBL-2  cells  induced  resistance 
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t 
Growth  of syngenelc  MBL-2  and  MBL-2.Fas  lymphoma 
cells in naive C57BL/6 and PKO mace. PKO or control C57BL/6 mice 
were injected  mtraperitoneally  with different  amounts  of viable MBL-2 
or MBL-2.Fas lymphoma cells m 0.25 ml PBS. Mice were observed daily 
for tumor  growth  by momtonng the  weight of the  mace. Mice were 
killed  if the  weight  increased  >15%  compared  to  uninjected  control 
mice.  Circles, MBL-2  cells, triangles, MBL-2.Fas  cells; filled  symbols, 
C57BL/6; open symbols, PKO. Each point represents one mouse.  Cumu- 
lative  data  of three  similar  experiments  (six rmce  per group  total)  are 
shown. 
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of per~bnn. Groups of mght perform-deficient and seven control C57BL/6 
rmce were treated tw]ce weekly wlth 3 nmol DMBA +  10 nmol TPA m 
acetone. The time of the appearance of the first papilloma was registered 
for each mouse. 
(Fig. 5, middle) or 400  Ixg (Fig. 5, bottom) induced sarcomas 
in C57BL/6  mice with an incidence of 80  and  100%,  re- 
spectively. At all doses, a significant accelerated onset of tu- 
mor (Fig. 5) and tumor size (data not shown) was observed 
in PKO mice. Administration of 100 Izg MCA  to CD8  /- 
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Figure 5.  Control of MCA-lnduced carcinogenesis by perforin. PKO 
(O), CD8  ~  (A) and control C57BL/6 (O) nuce were lnoected subcuta- 
neously in the left flank with 25, 100, or 400 mxg MCA m 0 1 ml corn o11. 
Mice were observed every 5 d for palpable tumors. If tumors were >15 
mm in diameter, m]ce were  killed. Experimental  groups consisted of 5 
(25 txg, 400  b~g) or 10 (100 Izg) mine. Differences between PKO and 
C57BL/6 rmce were statistically significant (unpaired Mann-Whitney U 
test), whereas differences between CD8 -j- and C57BL/6 mice were not 
against a  >104- and a  >103-fold higher dose of MBL-2 in 
C57BL/6  and  PKO  mice,  respectively.  In  C57BL/6  a 
>103-fold  and in PKO  an  103-fold higher protection was 
induced against MBL-2.Fas. 
Tumors hzduced by Chemical Carcinogens 
Subcutaneous injection of MCA  induced fibrosarcomas 
in  a  dose-dependent  fashion.  Injection of 25  bLg  (Fig.  5, 
top) induced tumors in 100% of the PKO, but only in 20% 
of the  C57BL/6  mice.  Administration  of  100  Ixg  MCA 
mice induced sarcomas with comparable kinetics and inci- 
dence as those seen in C57BL/6 mice. Experimental groups 
were  statistically  compared  using  the  unpaired  Mann- 
Whitney  U  test,  and  showed  that  tumor  development  In 
PKO mice and C57BL/6 mice was statistically different af- 
ter  injection  of  100  Ixg  MCA  (P  <0.0005)  or  400  I.Lg 
MCA  (P  <0.009).  The  difference  between  PKO  and 
CD8 -/-  mice was also statistically significant (P <0.0008), 
whereas  there  was  no  difference  between  C57BL/6  and 
CD8 -/  mice  (P  =  0.9).  Statistical  analysis was  not per- 
formed on groups injected with 25 I~g MCA, because only 
one  out of five  C57BL/6  mice, but five out of five PKO 
mice,  developed  a  sarcoma.  FACS  ®  analysis  performed 
within  10  d  after isolation of different MCA-lnduced  sar- 
comas  showed  that  the  sarcomas  were  MHC  class  I  I°w/-, 
MHC  class  II-,  and  Fas-  (not shown).  The  expression of 
the  above-mentioned surface  molecules was  similar in the 
three different strains of donor mice. 
The  first DMBA+TPA-induced  skin papillomas devel- 
oped in C57BL/6  and PKO  mice after  18 wk and 21  wk, 
respectively,  and  100%  incidence  was  reached  after  31.5 
and 34 wk,  respecnvely (Fig.  6). The incidence and kinet- 
ics  of DMBA+TPA-induced  papillomas  were  similar  in 
PKO  and  C57BL/6  mice,  arguing against  a  role  for  per- 
forin-mediated cytotoxicity (CTL and/or NK)  in the con- 
trol of DMBA+TPA-induced  papillomas. 
Virally Induced Fibrosarcomas 
Intramuscular  administration  of MoMSV  to  PKO  and 
C57BL/6  mice  led  to  tumor  induction in  all  mice  with 
similar kinetics.  In addition,  occurrence  of regression was 
not dependent on perforin  (Fig.  7).  Nevertheless,  the  tu- 
mors were larger on average and regression was retarded in 
PKO mice, suggesting involvement ofperforin in the acute 
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Figure  7.  Control of virally  induced tumors by PKO mice  PKO and 
control C57BL/6 nuce were given 103 focus forming units MoMSV in- 
tramuscularly in  100  Ixl PBS  in the left  hind leg.  Mice were momtored 
regularly for palpable  tumors. Each hne represents an individual  mouse 
effector phase of tumor rejection. CD8-depleted C57BL/6 
mice displayed similar tumor size and regression kinetics as 
PKO mice (not shown), indicating that CD8 ÷ T  cells,  and 
not  NK  cells,  exert  the  perforin-mediated  effect.  CD4- 
depleted  C57BL/6  mice,  on  the  other  hand,  developed 
large tumors that could not be eliminated (data not shown). 
We observed that PKO and C57BL/6 mice were sick and 
lost  weight when  the  tumor reached  its  peak size.  Treat- 
ment  with  anti-TNF-(x  antibody  abolished  this  sickness. 
Tumor size and kinetics  of regression,  however,  were not 
affected by this treatment. 
Discussion 
The perforin dependence of the eradication of several es- 
tablished  syngeneic tumor cell lines was investigated.  Most 
cell lines showed a difference in tumorigenic dose between 
naive PKO and C57BL/6 mice, indicating that even with- 
out  previous  priming,  perforin-mediated  cytotoxicity is  a 
crucial  effector  mechanism  in  tumor  control.  In  primed 
mice, the difference between PKO and wild-type mice was 
even more clear. This suggests that priming of CD8 + CTLs 
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rather than priming ofCD4 + T  cells is responsible for resis- 
tance to high tumor loads in C57BL/6 mice. 
Two  tumor cell lines formed an exception  to this  rule. 
RMA  cells  showed equal  growth in both naive  (104) and 
primed  (10  6)  PKO and C57BL/6 mice, which may be ex- 
plained  by the  fact  that  control  is  mediated  by perforin- 
independent mechanisms, probably by CD4 ÷ cells using an 
unidentified  effector  mechanism  (1).  Because  RMA  and 
MBL-2  are  related  lymphoma lines  and  express  similarly 
high levels of MHC  class I and no MHC  class II, and both 
cell  lines  are  Fas  l°w,  the  observation  that  the  control  of 
RMA is not dependent on perforin, whereas the control of 
MBL-2 cells is, was unexpected.  This may be explained by 
a  difference  in efficiency of priming CD4 +  and/or  CD8 + 
T  cells,  or by a different growth rate of RMA vs. MBL-2 
cells.  The second exception is formed by SR23B cells:  this 
adenovirus  +  ras-transformed  cell line  induced  larger  tu- 
mors  in  C57BL/6  mice  than  in  PKO  mice.  This  unex- 
pected finding may be explained by the fact that PKO mice 
may have  increased  basal  levels  of macrophage  activation 
and/or cytokines such as interferon-',/and TNF-oe as com- 
pensatory mechanisms,  all  of which  are known  to  possess 
antitumor activity. 
Stable  transfection  of MBL-2  cells  with  Fas  rendered 
them susceptible to Fas/FasL-dependent apoptosis in vitro. 
To  investigate  the  contribution  of the  Fas  pathway  to  in 
vivo tumor surveillance, control of MBL-2.Fas and MBL-2 
cells was compared in naive and primed PKO and C57BL/6 
mace. In unprimed PKO and C57BL/6 mice, Fas + cells were 
controlled  10-fold better  compared to  Fas-  cells.  Priming 
of PKO mice increased the number of tumor cells  needed 
for uncontrolled growth by 100-fold for both MBL-2  (10  4 
cells)  and for MBL-2.Fas  (10  s cells),  suggesting priming of 
perforin-independent  mechanisms.  Priming  of C57BL/6 
mice,  however,  resulted  in  control  of >106  MBL-2  or 
MBL-2.Fas cells, stressing the need for a collaboration be- 
tween  perforin-dependent  and  -independent  mechanisms 
for full immune protection against MBL-2 cells.  Thus,  our 
experiments  failed  to  detect  a  major involvement  of Fas- 
dependent  cytotoxicity in  tumor  control,  but  cannot  ex- 
clude a minor role. 
To investigate  the influence  of perforin  on the  induc- 
tion of primary tumors in vivo, we analyzed different mod- 
els  in  which  tumors  are  induced  by  chemicals  (MCA, 
DMBA+TPA)  or virus  (MoMSV).  The  major difference 
of this  approach  compared  to  injection  of syngeneic  cell 
lines  is  that  the  immune  system is  not  confronted with  a 
considerable  tumor load at once, but that immunosurveil- 
lance is  tested  at  the  very moment a  tumor arises.  More- 
over,  in  contrast  to  injection  of homogeneous  cell  lines, 
each mouse develops its own tumor that may have individ- 
ually different tumor antigens,  even if the same chemical is 
injected in the same animal (44). Subcutaneous injection of 
MCA is known to induce sarcomas at the site of injection 
(44)  that  usually  do  not  regress  once  they  developed. 
C57BL/6  and  CD8  /  mice  developed  sarcomas  with  a 
high  incidence  but  with  much  slower kinetics  than  PKO 
mice. This suggests that NK cells  or CD4 + T  cells  may act directly  or  indirectly  as  important  effectors  controlling 
MCA-induced sarcomas. Ex vivo analysis of MHC  class I, 
class  II,  and  Fas  expression  of MCA-induced  sarcomas, 
however, showed that sarcomas were Fas  and MHC  class 
II-  and  were  MHC  class I -/l°w,  independent  of whether 
they were isolated from PKO, C57BL/6,  or CD8  /  mice. 
Although MHC  class I expression could be upregulated to 
high levels by exposure to IFN-',/ in vitro  (not shown),  it 
remains unclear whether this occurs in vivo. Because four 
out of four MCA-induced sarcomas tested were sensitive to 
NK-mediated lysis in vitro, this suggests that NK-mediated 
control may be an important pathway in vivo. In a second 
set  of experiments in  which  DMBA+TPA-induced  skin 
papillomas were studied, no differences in incidence, kinet- 
ics, or size of papillomas were observed between PKO and 
C57BL/6 mice, indicating that perforin does not play a key 
role. Because the latter model is immunologically not char- 
acterized  (susceptibility  of  SCID  or  nu/nu  mice  is  not 
known),  it ~s not possible at the present time to be more 
specific about possible effector mechanisms. 
Sarcomas induced by inoculation of mice with MoMSV 
are known to be rejected within 3  wk by immunocompe- 
tent mice in which a prominent H-2Db-restricted CTL re- 
sponse is observed (45-48),  whereas lethal tumors develop 
in nu/nu mice (Ossendorp, F., and C.J.M.  Melief, unpub- 
lished data). Furthermore, CD4 depletion results in uncon- 
trolled tumor growth  (Ossendorp,  F.,  and  C.J.M.  Melief, 
unpublished data). CD8  depletion, on the other hand,  did 
not alter the incidence or kinetics of tumor growth, but led 
to a significant delay in tumor rejection (data not shown). 
PKO mice &splayed a phenotype similar to CDS-depleted 
mice after inoculation w~th MoMSV,  suggesting a distinct, 
perforin-dependent role for CD8 + CTLs in tumor control, 
although  the  tumor  could be  rejected without  this  path- 
way.  It is  not  known  at  the  present  time  which  effector 
mechanism  is  used  by  CD4 +  T  cells to  reject MoMSV- 
induced  sarcomas,  and  this  question  is  subject  to  further 
stu&es. Apparently, CD4 + T  cells do not eradicate tumors 
through TNF-ot because treatment with neutralizing anti- 
TNF  antibodies in vivo improved the  general well-being 
of the mice at the peak of the tumor growth,  but did not 
interfere with  tumor rejection (data not  shown)  indepen- 
dent of mouse strain or treatment. 
Finally, during the  3  yr we  now  have  bred PKO  mice 
and have kept some ("-'100) for >12 mo, we have not ob- 
served spontaneous tumors of any kind. This does not nec- 
essarily call into question the in vivo relevance of perforin 
for tumor control because (a) a mouse facility is a relatively 
protected environment  in which  mice are not  exposed to 
irradiation, toxins, chemicals, or exogenous oncogenic vi- 
ruses; and (b) spontaneous tumor development may be too 
rare for meaningful observation in the few mice that were 
not used for experiments when young and reached an age 
of >1  yr in our facilities. 
Taken  together,  our  data  illustrate that  several mecha- 
nisms may control tumor growth; perforin-mediated cyto- 
toxicity by  CD8 ÷  CTLs  (for  MHC  class  I ÷  tumors)  and 
NK cells (for tumors expressing low levels of MHC  class I) 
are of major importance; Fas/FasL interactions can contrib- 
ute to tumor control in vivo, albeit to a lesser extent than 
perforin-dependent  lysis,  at  least  in  tumor  models  using 
several  established  tumor  cell  lines  or  primarily induced 
types of tumors studied here. 
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